Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HPST Hempstract	$0.00	$0.00	$0.00 ▼ $0.01	$483K	-3.19	6,416 shs	N/A
NMHLY NMC Health	$0.00	$0.00	$0.00 ▼ $0.18	N/A	-5.26	16,591 shs	100 shs
VIRI Virios Therapeutics	$0.47 +2.2%	$0.41	$0.28 ▼ $2.42	$9.04M	1.88	342,970 shs	39,799 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HPST Hempstract	0.00%	+9.68%	+36.00%	+36.00%	+9.68%
NMHLY NMC Health	0.00%	0.00%	0.00%	0.00%	-92.00%
VIRI Virios Therapeutics	+3.01%	+7.81%	-2.94%	+14.51%	-39.44%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HPST Hempstract	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NMHLY NMC Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HPST Hempstract	N/A	N/A	N/A	N/A
NMHLY NMC Health	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HPST Hempstract	N/A	N/A	N/A	N/A	N/A	N/A
NMHLY NMC Health	N/A	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HPST Hempstract	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NMHLY NMC Health	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.28	N/A	N/A	N/A	N/A	-110.15%	-100.18%	5/9/2024 (Estimated)

Latest NMHLY, HPST, IDH, and VIRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	VIRI Virios Therapeutics	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HPST Hempstract	N/A	N/A	N/A	N/A	N/A
NMHLY NMC Health	$0.20	98,000.00%	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HPST Hempstract	N/A	N/A	N/A
NMHLY NMC Health	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	11.60	11.60

Ownership

Institutional Ownership

Company	Institutional Ownership
HPST Hempstract	N/A
NMHLY NMC Health	N/A
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
HPST Hempstract	28.10%
NMHLY NMC Health	N/A
VIRI Virios Therapeutics	11.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HPST Hempstract	2	142.09 million	102.16 million	Not Optionable
NMHLY NMC Health	17,748	N/A	N/A	Not Optionable
VIRI Virios Therapeutics	4	19.26 million	17.01 million	Optionable

NMHLY, HPST, IDH, and VIRI Headlines

Source	Headline
	Virios Therapeutics, Inc. (VIRI) finance.yahoo.com - April 14 at 7:23 PM
	Virios Therapeutics seeks global patent for antiviral combo investing.com - March 28 at 11:45 PM
	Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID globenewswire.com - March 26 at 9:15 AM
	Virios Therapeutics announces salary cuts for employees and board investing.com - February 29 at 5:35 PM
	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results markets.businessinsider.com - February 29 at 12:35 PM
	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results globenewswire.com - February 29 at 9:15 AM
	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones markets.businessinsider.com - February 28 at 11:24 AM
	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones globenewswire.com - February 28 at 9:15 AM
	Virios Therapeutics Llc (VIRI) investing.com - February 27 at 7:37 AM
	Virios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08 msn.com - February 25 at 12:10 AM
	Virios Therapeutics Inc Ordinary Shares VIRI morningstar.com - February 9 at 12:13 AM
	VIRI: Moving IMC-2 into Phase 2 Program in Long COVID finance.yahoo.com - February 7 at 1:09 PM
	Fibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research Nester finance.yahoo.com - February 6 at 3:37 PM
	Virios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and Dates benzinga.com - January 23 at 10:37 PM
	Virios Therapeutics to advance development of IMC-2 as treatment for symptoms associated with long-Covid pharmabiz.com - January 23 at 7:35 AM
	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID finanznachrichten.de - January 22 at 3:19 PM
	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID finance.yahoo.com - January 22 at 10:18 AM
	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development ... bakersfield.com - January 2 at 9:21 AM
	Virios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2 markets.businessinsider.com - January 2 at 9:21 AM
	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID finance.yahoo.com - January 2 at 9:21 AM
	Taking a Closer Look At Virios Therapeutics Inc (VIRI) Following Its Recent Trade knoxdaily.com - January 1 at 8:34 AM
	Virios Therapeutics Inc Ordinary Shares morningstar.com - December 7 at 10:47 PM
	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 14 at 1:38 PM
	VIRI: Provides Overview of Phase 3 Program in Fibromyalgia finance.yahoo.com - November 13 at 3:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Hempstract

OTCMKTS:HPST

Hempstract, Inc. produces and sells cannabidiol (CBD) and cannabigerol solutions in the United States. It offers CBD isolate powder and distillate oil. The company was formerly known as Riverdale Oil and Gas Corporation and changed its name to Hempstract, Inc. in November 2020. Hempstract, Inc. is based in Warden, Washington.

NMC Health

OTCMKTS:NMHLY

NMC Health plc provides healthcare services in the United Arab Emirates, the United Kingdom, Spain, and internationally. The company owns and manages healthcare facilities, including hospitals, medical centers, long term care facilities, day surgery centers, fertility clinics, and home health services providers. The company offers medical services comprising diagnostic, and in and outpatient services, as well as research and medical services in the field of gynecology, obstetrics, and human reproduction; and management services in respect of hospitals, as well as retails pharmaceutical goods. NMC Health plc was founded in 1974 and is based in London, United Kingdom.

Virios Therapeutics

NASDAQ:VIRI

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial